JP2007525512A - Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしての３，４−（シクロペンチル）−縮合プロリン化合物 - Google Patents
Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしての３，４−（シクロペンチル）−縮合プロリン化合物 Download PDFInfo
- Publication number
- JP2007525512A JP2007525512A JP2007500950A JP2007500950A JP2007525512A JP 2007525512 A JP2007525512 A JP 2007525512A JP 2007500950 A JP2007500950 A JP 2007500950A JP 2007500950 A JP2007500950 A JP 2007500950A JP 2007525512 A JP2007525512 A JP 2007525512A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- hcv
- group
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCCC(*)C(C(NCC=C)=O)O Chemical compound CCCC(*)C(C(NCC=C)=O)O 0.000 description 17
- DPFCMHQQTKBKAX-VUWPPUDQSA-N CCC[C@@H](C(C(NC1CC1)=O)O)NC(OC(C)(C)C)=O Chemical compound CCC[C@@H](C(C(NC1CC1)=O)O)NC(OC(C)(C)C)=O DPFCMHQQTKBKAX-VUWPPUDQSA-N 0.000 description 2
- GRDAUQGUZNPYIP-XMCUXHSSSA-N CC(C([C@@H](CCC1)[C@@H]1C1)N1NC)=O Chemical compound CC(C([C@@H](CCC1)[C@@H]1C1)N1NC)=O GRDAUQGUZNPYIP-XMCUXHSSSA-N 0.000 description 1
- JHSLRLUDDORMLM-JVIMKECRSA-N CC(C([C@H]1CC2)N(C)C[C@@H]1C2(F)F)=O Chemical compound CC(C([C@H]1CC2)N(C)C[C@@H]1C2(F)F)=O JHSLRLUDDORMLM-JVIMKECRSA-N 0.000 description 1
- DQTVOWNRRLNDEY-UHFFFAOYSA-N CC(C)(C)OC(NCC(C(OC)=O)O)=O Chemical compound CC(C)(C)OC(NCC(C(OC)=O)O)=O DQTVOWNRRLNDEY-UHFFFAOYSA-N 0.000 description 1
- GWUFWSKCLJKBMQ-UHFFFAOYSA-N CC(C)(C)S(CC1(CCCCC1)N=C=O)(=O)=O Chemical compound CC(C)(C)S(CC1(CCCCC1)N=C=O)(=O)=O GWUFWSKCLJKBMQ-UHFFFAOYSA-N 0.000 description 1
- GMBRYZXXJWFPIU-JNCQHCEUSA-N CC(C)(C)[C@@H](C(N(C[C@H]1[C@@H]2CCC1)[C@@H]2C(NC(CC1CCC1)C(C(N)=O)O)=O)=O)NC(OC(C)(C)C)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@H]1[C@@H]2CCC1)[C@@H]2C(NC(CC1CCC1)C(C(N)=O)O)=O)=O)NC(OC(C)(C)C)=O GMBRYZXXJWFPIU-JNCQHCEUSA-N 0.000 description 1
- OWONYHWWZMRTCN-XDQVBPFNSA-N CC(C)(C)[C@@H](C(N(C[C@H]1[C@@H]2CCC1)[C@@H]2C(O)=O)=O)NC(OC(C)(C)C)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@H]1[C@@H]2CCC1)[C@@H]2C(O)=O)=O)NC(OC(C)(C)C)=O OWONYHWWZMRTCN-XDQVBPFNSA-N 0.000 description 1
- MGOZVPWQENBJLS-DLWHVABMSA-N CC(C)(C)[C@@H](CN(C(CC(C)(C)C1)=O)C1=O)NC(N[C@@H](C(C)(C)C)C(N(C[C@H]1[C@@H]2CCC1)[C@@H]2C(O)=O)=O)=O Chemical compound CC(C)(C)[C@@H](CN(C(CC(C)(C)C1)=O)C1=O)NC(N[C@@H](C(C)(C)C)C(N(C[C@H]1[C@@H]2CCC1)[C@@H]2C(O)=O)=O)=O MGOZVPWQENBJLS-DLWHVABMSA-N 0.000 description 1
- MINDURRISKIVOD-GFCCVEGCSA-N CC(C)(C)[C@@H](CN(C(c1c2cccc1)=O)C2=O)N=C=O Chemical compound CC(C)(C)[C@@H](CN(C(c1c2cccc1)=O)C2=O)N=C=O MINDURRISKIVOD-GFCCVEGCSA-N 0.000 description 1
- KFAGKWXINMRUQW-CTNUACJYSA-N CC(C)(C)[C@@H](CN(C(c1c2cccc1)=O)C2=O)NC(N[C@@H](C(C)(C)C)C(N(C[C@H]1[C@@H]2CCC1)[C@@H]2C(NC(CC1CCC1)C(C(N)=O)=O)=O)=O)=O Chemical compound CC(C)(C)[C@@H](CN(C(c1c2cccc1)=O)C2=O)NC(N[C@@H](C(C)(C)C)C(N(C[C@H]1[C@@H]2CCC1)[C@@H]2C(NC(CC1CCC1)C(C(N)=O)=O)=O)=O)=O KFAGKWXINMRUQW-CTNUACJYSA-N 0.000 description 1
- NTUCQKRAQSWLOP-UHFFFAOYSA-N CC(C)OCc1ccccc1 Chemical compound CC(C)OCc1ccccc1 NTUCQKRAQSWLOP-UHFFFAOYSA-N 0.000 description 1
- WQNDAVGXCMQSSH-UHFFFAOYSA-N CC(CC1)CCC1(F)F Chemical compound CC(CC1)CCC1(F)F WQNDAVGXCMQSSH-UHFFFAOYSA-N 0.000 description 1
- JQPXODYTXVAIHS-QRHSGQBVSA-N CC1(C)C[C@@H]2C(C(C)=O)N(C)C[C@@H]2C1 Chemical compound CC1(C)C[C@@H]2C(C(C)=O)N(C)C[C@@H]2C1 JQPXODYTXVAIHS-QRHSGQBVSA-N 0.000 description 1
- OVRKATYHWPCGPZ-UHFFFAOYSA-N CC1CCOCC1 Chemical compound CC1CCOCC1 OVRKATYHWPCGPZ-UHFFFAOYSA-N 0.000 description 1
- HEFMGNBODKFVNU-SDUMOIGESA-N CCCC(C(C(NCC=C)=O)=O)NC([C@H]([C@@H](CCC1)[C@@H]1C1)N1C(C(C#CC(C)(C)C)NC(N[C@H](CN(C(CC(C)(C)C1)=O)C1=O)C(C)(C)C)=O)=O)=O Chemical compound CCCC(C(C(NCC=C)=O)=O)NC([C@H]([C@@H](CCC1)[C@@H]1C1)N1C(C(C#CC(C)(C)C)NC(N[C@H](CN(C(CC(C)(C)C1)=O)C1=O)C(C)(C)C)=O)=O)=O HEFMGNBODKFVNU-SDUMOIGESA-N 0.000 description 1
- FKHMLGNVDMDUJO-WEIXLVGNSA-N CCCC(C(C(NCC=C)=O)O)NC([C@H]([C@@H](CCC1)[C@@H]1C1)N1C([C@H](C(C)C(C)C)NC(N[C@H](CN(C(CC(C)(C)C1)=O)C1=O)C(C)(C)C)=O)=O)=O Chemical compound CCCC(C(C(NCC=C)=O)O)NC([C@H]([C@@H](CCC1)[C@@H]1C1)N1C([C@H](C(C)C(C)C)NC(N[C@H](CN(C(CC(C)(C)C1)=O)C1=O)C(C)(C)C)=O)=O)=O FKHMLGNVDMDUJO-WEIXLVGNSA-N 0.000 description 1
- VAHVRQDZGUPKBR-AMBJYNMOSA-N CCC[C@@H](C(C(NC1CC1)=O)=O)NC([C@H]([C@@H](CCC1)[C@@H]1C1)N1C([C@H](C(C)(C)C)NC(N[C@H](CN(C(CC(C)(C)C1)=O)C1=O)C(C)(C)C)=O)=O)=O Chemical compound CCC[C@@H](C(C(NC1CC1)=O)=O)NC([C@H]([C@@H](CCC1)[C@@H]1C1)N1C([C@H](C(C)(C)C)NC(N[C@H](CN(C(CC(C)(C)C1)=O)C1=O)C(C)(C)C)=O)=O)=O VAHVRQDZGUPKBR-AMBJYNMOSA-N 0.000 description 1
- UMBJIHSHCLDUFA-UEWDXFNNSA-N CCC[C@@H](C(C(NC1CC1)=O)OC(C)=O)NC(OC(C)(C)C)=O Chemical compound CCC[C@@H](C(C(NC1CC1)=O)OC(C)=O)NC(OC(C)(C)C)=O UMBJIHSHCLDUFA-UEWDXFNNSA-N 0.000 description 1
- ITKMQSJDMFEBTD-UHFFFAOYSA-N CCOC(CSC(C)(C)N)=O Chemical compound CCOC(CSC(C)(C)N)=O ITKMQSJDMFEBTD-UHFFFAOYSA-N 0.000 description 1
- QMCSJBNHPXKELK-JFHOBNPCSA-N CCS(CC1(CCCCC1)NC(N[C@@H](C(C)(C)C)C(N(C[C@H]1[C@@H]2CCC1)[C@@H]2C(NC(CCC#C)C(C(NCC=C)=O)=O)=O)=O)=O)(=O)=O Chemical compound CCS(CC1(CCCCC1)NC(N[C@@H](C(C)(C)C)C(N(C[C@H]1[C@@H]2CCC1)[C@@H]2C(NC(CCC#C)C(C(NCC=C)=O)=O)=O)=O)=O)(=O)=O QMCSJBNHPXKELK-JFHOBNPCSA-N 0.000 description 1
- WDLAKWKXQBQGPE-HQMXNFIDSA-N CC[C@@H](C(N(C[C@H]1[C@@H]2CCC1)[C@@H]2C(O)=O)=O)NC(N[C@H](CN(C(CC(C)(C)C1)=O)C1=O)C(C)(C)C)=O Chemical compound CC[C@@H](C(N(C[C@H]1[C@@H]2CCC1)[C@@H]2C(O)=O)=O)NC(N[C@H](CN(C(CC(C)(C)C1)=O)C1=O)C(C)(C)C)=O WDLAKWKXQBQGPE-HQMXNFIDSA-N 0.000 description 1
- SXWVWILPQBTINJ-UHFFFAOYSA-N COC(C1(COS(C)(=O)=O)CCCCC1)=O Chemical compound COC(C1(COS(C)(=O)=O)CCCCC1)=O SXWVWILPQBTINJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54865504P | 2004-02-27 | 2004-02-27 | |
| PCT/US2005/005778 WO2005087730A1 (en) | 2004-02-27 | 2005-02-24 | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007525512A true JP2007525512A (ja) | 2007-09-06 |
| JP2007525512A5 JP2007525512A5 (https=) | 2008-03-27 |
Family
ID=34961939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007500950A Pending JP2007525512A (ja) | 2004-02-27 | 2005-02-24 | Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしての３，４−（シクロペンチル）−縮合プロリン化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7342041B2 (https=) |
| EP (1) | EP1737821B1 (https=) |
| JP (1) | JP2007525512A (https=) |
| CN (1) | CN1946692A (https=) |
| AR (1) | AR048413A1 (https=) |
| AT (1) | ATE438622T1 (https=) |
| CA (1) | CA2557307A1 (https=) |
| DE (1) | DE602005015834D1 (https=) |
| ES (1) | ES2328589T3 (https=) |
| TW (1) | TWI302835B (https=) |
| WO (1) | WO2005087730A1 (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP1019A (en) | 1996-10-18 | 2001-10-16 | Vertex Pharma | Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease. |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| ITRE20010042A1 (it) * | 2001-04-24 | 2002-10-24 | Corghi Spa | Dispositivo sollevatore per macchine smontagomme |
| JP2003007697A (ja) * | 2001-06-21 | 2003-01-10 | Hitachi Kokusai Electric Inc | 半導体装置の製造方法、基板処理方法および基板処理装置 |
| UY28500A1 (es) | 2003-09-05 | 2005-04-29 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc. |
| US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| WO2005087721A2 (en) * | 2004-02-27 | 2005-09-22 | Schering Corporation | Compounds as inhibitors of hepatitis c virus ns3 serine protease |
| AU2005219824B2 (en) * | 2004-02-27 | 2007-11-29 | Merck Sharp & Dohme Corp. | Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus |
| NZ563365A (en) * | 2005-06-02 | 2011-02-25 | Schering Corp | Combination of HCV protease inhibitors with a surfactant |
| US20060276404A1 (en) * | 2005-06-02 | 2006-12-07 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
| NZ563361A (en) | 2005-06-02 | 2011-02-25 | Schering Corp | HCV protease inhibitors in combination with food |
| US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
| AU2006276246B2 (en) * | 2005-07-25 | 2012-09-27 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis C virus replication |
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| WO2007022459A2 (en) | 2005-08-19 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| ES2356776T3 (es) * | 2005-10-11 | 2011-04-13 | Intermune, Inc. | Compuestos y métodos para inhibir la replicación del virus de la hepatitis. |
| EP2392589A3 (en) | 2005-11-11 | 2012-06-20 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| US8183413B2 (en) | 2006-01-20 | 2012-05-22 | Kaneka Corporation | Process for production of β-amino-α-hydroxy carboxamide derivative |
| US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| AU2007217355B2 (en) | 2006-02-27 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same |
| JP2009132621A (ja) * | 2006-03-13 | 2009-06-18 | Ajinomoto Co Inc | シクロプロピルアミド化合物の製造方法 |
| WO2007109080A2 (en) | 2006-03-16 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
| RU2008144294A (ru) * | 2006-04-11 | 2010-05-20 | Новартис АГ (CH) | Ингибиторы вируса гепатита с (hcv) |
| AU2007249668B2 (en) * | 2006-04-11 | 2011-04-07 | Novartis Ag | HCV/HIV inhibitors and their uses |
| US20080045530A1 (en) * | 2006-04-11 | 2008-02-21 | Trixi Brandl | Organic Compounds and Their Uses |
| WO2007138928A1 (ja) | 2006-05-26 | 2007-12-06 | Kaneka Corporation | 光学活性３－アミノ－２－ヒドロキシプロピオン酸シクロプロピルアミド誘導体およびその塩の製造方法 |
| DE102006059317A1 (de) * | 2006-07-04 | 2008-01-10 | Evonik Degussa Gmbh | Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| RU2009109355A (ru) | 2006-08-17 | 2010-09-27 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Ингибиторы вырусной полимеразы |
| US20100081672A1 (en) * | 2006-12-07 | 2010-04-01 | Schering Corporation | Ph sensitive matrix formulation |
| WO2008106058A2 (en) | 2007-02-27 | 2008-09-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| HRP20120330T1 (hr) | 2007-02-27 | 2012-05-31 | Vertex Pharmaceuticals Incorporated | Sukristali i farmaceutski pripravci koji ih sadrže |
| SG174809A1 (en) * | 2007-05-03 | 2011-10-28 | Intermune Inc | Macrocyclic compounds useful as inhibitors of hepatitis c virus |
| JP2010526834A (ja) * | 2007-05-10 | 2010-08-05 | インターミューン・インコーポレーテッド | Ｃ型肝炎ウイルス複製の新規ペプチド阻害剤 |
| US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| NZ583699A (en) | 2007-08-30 | 2012-04-27 | Vertex Pharma | Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same |
| CN101868452B (zh) * | 2007-10-10 | 2014-08-06 | 诺华股份有限公司 | 螺环吡咯烷类与其对抗hcv和hiv感染的应用 |
| US8106059B2 (en) * | 2007-10-24 | 2012-01-31 | Virobay, Inc. | Substituted pyrazines that inhibit protease cathepsin S and HCV replication |
| EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
| WO2009142842A2 (en) | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| CN102816106A (zh) * | 2008-06-24 | 2012-12-12 | 默沙东公司 | 用于制备基本上立体异构纯的稠合二环脯氨酸化合物的生物催化方法 |
| CN102271699A (zh) | 2009-01-07 | 2011-12-07 | 西尼克斯公司 | 用于治疗hcv和hiv感染的环孢菌素衍生物 |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| US20110182850A1 (en) * | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| US8512690B2 (en) * | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| CA2763140A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
| JP2013512246A (ja) | 2009-11-25 | 2013-04-11 | メルク・シャープ・アンド・ドーム・コーポレーション | ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体 |
| US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
| EA201290882A1 (ru) | 2010-03-09 | 2013-04-30 | Мерк Шарп Энд Домэ Корп. | Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний |
| WO2012018534A2 (en) | 2010-07-26 | 2012-02-09 | Schering Corporation | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| JP2013540122A (ja) | 2010-09-29 | 2013-10-31 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法 |
| WO2012142075A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| BR112013026345A2 (pt) | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv |
| WO2012158515A1 (en) * | 2011-05-13 | 2012-11-22 | Vertex Phamaceuticals Incorporated | Process for the preparation of protease inhibitors |
| WO2012158513A1 (en) * | 2011-05-13 | 2012-11-22 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
| WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
| US20140378416A1 (en) | 2011-09-14 | 2014-12-25 | Michael P. Dwyer | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| AR091192A1 (es) | 2012-05-30 | 2015-01-21 | Chemo Iberica Sa | Procedimiento multicomponente para la preparacion de compuestos biciclicos |
| CN103508918B (zh) * | 2012-06-18 | 2015-09-09 | 上海医药工业研究院 | 带有环丁基的α-羟基β-氨基酯类化合物及其制备方法 |
| ITMI20122205A1 (it) * | 2012-12-20 | 2014-06-21 | Dipharma Francis Srl | Sintesi di un intermedio di un inibitore delle proteasi virali |
| CN103387510B (zh) * | 2013-08-08 | 2015-09-09 | 苏州永健生物医药有限公司 | 一种β-氨基-alpha-羟基环丁基丁酰胺盐酸盐的合成方法 |
| WO2015065817A1 (en) | 2013-10-30 | 2015-05-07 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
| CN103664739B (zh) * | 2013-12-10 | 2016-04-27 | 湖南科源生物制品有限公司 | 一种特拉匹韦中间体的制备方法 |
| CN104926712B (zh) * | 2014-03-20 | 2018-03-23 | 上海医药工业研究院 | 合成特拉匹韦的中间体及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002018369A2 (en) * | 2000-08-31 | 2002-03-07 | Eli Lilly And Company | Peptidomimetic protease inhibitors |
| WO2003062265A2 (en) * | 2002-01-18 | 2003-07-31 | Schering Corporation | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| JP2004504404A (ja) * | 2000-07-21 | 2004-02-12 | シェリング・コーポレーション | Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ227011A (en) | 1987-11-18 | 1992-03-26 | Chiron Corp | Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits |
| EP0381216B1 (en) | 1989-02-01 | 1995-12-27 | Asahi Glass Company Ltd. | Hydrochlorofluorocarbon azeotropic or azeotropic-like mixture |
| ATE270326T1 (de) | 1990-04-04 | 2004-07-15 | Chiron Corp | Protease von hepatitis-c-virus |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
| AR022061A1 (es) * | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| JP2000256396A (ja) * | 1999-03-03 | 2000-09-19 | Dainippon Pharmaceut Co Ltd | 複素環式化合物およびその中間体ならびにエラスターゼ阻害剤 |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| AU2001251165A1 (en) | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| ES2317900T3 (es) | 2000-04-05 | 2009-05-01 | Schering Corporation | Inhibidores de serina proteasa ns3 macrociclicos del virus de la hepatitis c que comprenden fragmentos n-ciclicas p2. |
| AU2001253621A1 (en) | 2000-04-19 | 2001-11-07 | Schering Corporation | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties |
| WO2002008251A2 (en) | 2000-07-21 | 2002-01-31 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
| SK742003A3 (en) | 2000-07-21 | 2003-06-03 | Schering Corp | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| AU3659102A (en) | 2000-12-12 | 2002-06-24 | Schering Corp | Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
| US7456629B2 (en) | 2006-07-11 | 2008-11-25 | Continental Automotive Systems Us, Inc. | Rotary angle sensing system |
-
2005
- 2005-02-24 DE DE602005015834T patent/DE602005015834D1/de not_active Expired - Lifetime
- 2005-02-24 US US11/064,757 patent/US7342041B2/en not_active Expired - Fee Related
- 2005-02-24 ES ES05723594T patent/ES2328589T3/es not_active Expired - Lifetime
- 2005-02-24 AT AT05723594T patent/ATE438622T1/de not_active IP Right Cessation
- 2005-02-24 EP EP05723594A patent/EP1737821B1/en not_active Expired - Lifetime
- 2005-02-24 JP JP2007500950A patent/JP2007525512A/ja active Pending
- 2005-02-24 CA CA002557307A patent/CA2557307A1/en not_active Abandoned
- 2005-02-24 WO PCT/US2005/005778 patent/WO2005087730A1/en not_active Ceased
- 2005-02-24 AR ARP050100678A patent/AR048413A1/es not_active Application Discontinuation
- 2005-02-24 CN CNA2005800128574A patent/CN1946692A/zh active Pending
- 2005-02-25 TW TW094105708A patent/TWI302835B/zh not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004504404A (ja) * | 2000-07-21 | 2004-02-12 | シェリング・コーポレーション | Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド |
| WO2002018369A2 (en) * | 2000-08-31 | 2002-03-07 | Eli Lilly And Company | Peptidomimetic protease inhibitors |
| WO2003062265A2 (en) * | 2002-01-18 | 2003-07-31 | Schering Corporation | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
Also Published As
| Publication number | Publication date |
|---|---|
| US7342041B2 (en) | 2008-03-11 |
| DE602005015834D1 (de) | 2009-09-17 |
| EP1737821B1 (en) | 2009-08-05 |
| US20050197301A1 (en) | 2005-09-08 |
| CA2557307A1 (en) | 2005-09-22 |
| EP1737821A1 (en) | 2007-01-03 |
| ES2328589T3 (es) | 2009-11-16 |
| TW200536530A (en) | 2005-11-16 |
| AR048413A1 (es) | 2006-04-26 |
| HK1095820A1 (en) | 2007-05-18 |
| WO2005087730A1 (en) | 2005-09-22 |
| CN1946692A (zh) | 2007-04-11 |
| TWI302835B (en) | 2008-11-11 |
| ATE438622T1 (de) | 2009-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4874227B2 (ja) | Ｃ型肝炎ウイルスのｎｓ３セリンプロテアーゼインヒビターとしての環状ｐ４’ｓを有する新規ケトアミド | |
| JP4745327B2 (ja) | Ｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター | |
| US7342041B2 (en) | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease | |
| US7485625B2 (en) | Inhibitors of hepatitis C virus NS3/NS4a serine protease | |
| JP4714732B2 (ja) | Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしての硫黄化合物 | |
| US7718691B2 (en) | Compounds as inhibitors of hepatitis C virus NS3 serine protease | |
| US7550559B2 (en) | Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease | |
| US7186747B2 (en) | Compounds as inhibitors of hepatitis C virus NS3 serine protease | |
| US7399749B2 (en) | Substituted prolines as inhibitors of hepatitis C virus NS3 serine protease | |
| US7635694B2 (en) | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease | |
| JP2007532479A (ja) | Ｃ型肝炎ウイルスｎｓ３プロテアーゼの脱ペプチド化インヒビター | |
| JP2007525521A (ja) | Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしてのシクロブテンジオン基含有化合物 | |
| MXPA06009815A (en) | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| HK1095820B (en) | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| MXPA06009811A (en) | Compounds as inhibitors of hepatitis c virus ns3 serine protease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080207 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080207 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101207 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110303 Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110303 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110310 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110406 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111005 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120228 |